Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | REN | P00797 | 8/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072329 | 0.83 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL8171105 | 0.80 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL663112 | 0.80 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL5072308 | 0.77 | SLC6A4 (0.76) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL65337 | 0.77 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL79378 | 0.77 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL65338 | 0.77 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL2284094 | 0.72 | REN (0.54) | KCNH2CYP3A4REN | |
| SCHEMBL66535 | 0.71 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL662733 | 0.70 | REN (0.53) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20090029964-A1 | Novel carbapenem compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | SLC6A4 1352/4885SLC6A2 374/4885SLC6A3 782/4885 |
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | SLC6A4 413/4885SLC6A2 73/4885SLC6A3 171/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | SLC6A4 2577/4885SLC6A2 912/4885SLC6A3 1838/4885 |
| US-20090029964-A1 | Novel carbapenem compound | MGAM2, OXA1L, RIOX2 | SLC6A4 4874/4885SLC6A2 4299/4885SLC6A3 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.